Cresanto Global Limited Reports Q3FY26 Results with Net Loss of ₹9.44 Lakhs
Cresanto Global Limited reported Q3FY26 results showing a net loss of ₹9.44 lakhs, improved from ₹24.91 lakhs loss in Q3FY25. The company had no operational revenue during the quarter, with total income of ₹2.00 lakhs from other sources. Total expenses decreased to ₹11.44 lakhs from ₹25.77 lakhs year-over-year. For the nine-month period, net loss reduced to ₹19.49 lakhs from ₹28.33 lakhs in the previous year, indicating gradual improvement in financial performance.
*this image is generated using AI for illustrative purposes only.
Cresanto Global Limited (formerly Raymed Labs Limited) has announced its unaudited financial results for the third quarter ended December 31, 2025, revealing continued operational challenges with a net loss of ₹9.44 lakhs. The Board of Directors approved these results during a meeting held on February 4, 2026.
Financial Performance Overview
The company's financial performance for Q3FY26 showed mixed results compared to previous periods. While the quarterly loss narrowed significantly from the previous year, operational revenue remained absent during the quarter.
| Financial Metric: | Q3FY26 | Q3FY25 | Q2FY26 | Change (Q3FY26 vs Q3FY25) |
|---|---|---|---|---|
| Revenue from Operations: | - | - | ₹5.39 lakhs | No change |
| Other Income: | ₹2.00 lakhs | ₹0.86 lakhs | - | +132.56% |
| Total Income: | ₹2.00 lakhs | ₹0.86 lakhs | ₹5.39 lakhs | +132.56% |
| Net Loss: | ₹9.44 lakhs | ₹24.91 lakhs | ₹0.85 lakhs | Improvement of 62.10% |
Expense Analysis
The company's total expenses for Q3FY26 amounted to ₹11.44 lakhs, significantly lower than the ₹25.77 lakhs recorded in Q3FY25. The major expense components included employee benefits expenses of ₹6.40 lakhs and other expenses of ₹5.04 lakhs.
| Expense Category: | Q3FY26 | Q3FY25 | Q2FY26 |
|---|---|---|---|
| Employee Benefits: | ₹6.40 lakhs | ₹0.40 lakhs | ₹0.60 lakhs |
| Other Expenses: | ₹5.04 lakhs | ₹25.22 lakhs | ₹0.42 lakhs |
| Purchases of Stock in Trade: | - | - | ₹5.22 lakhs |
| Total Expenses: | ₹11.44 lakhs | ₹25.77 lakhs | ₹6.24 lakhs |
Nine-Month Performance
For the nine-month period ended December 31, 2025, Cresanto Global reported improved performance compared to the corresponding period in the previous year. The company's net loss reduced to ₹19.49 lakhs from ₹28.33 lakhs in the nine months ended December 31, 2024.
Earnings Per Share
The basic and diluted earnings per share for Q3FY26 stood at ₹(0.22) compared to ₹(0.58) in Q3FY25, reflecting the reduced loss per share. For the nine-month period, the earnings per share improved to ₹(0.46) from ₹(0.66) in the corresponding period last year.
Corporate Information
Cresanto Global Limited, formerly known as Raymed Labs Limited, operates with its corporate office in Mumbai and registered office in Noida. The company's results were reviewed by K T P S & Co., Chartered Accountants, who provided a limited review report confirming compliance with applicable accounting standards and regulations.
19
